literature

HIV mutation literature information.

High resistance to reverse transcriptase inhibitors among persons infected with human immunodeficiency virus type 1 subtype circulating recombinant form 02_AG in Ghana and on antiretroviral therapy.

PMID: 32049783 2020 Medicine

Discussion: M184 V also increases susceptibility to Zidovudine, Stavudine, and Tenofovir, and is associated with a clinically significant reduction in HIV-1 replication in vivo.

Discussion: Due to the decrease in susceptibility, patients infected with HIV-1 with the M184 V mutation continue treatment with Lamivudine, resulting in continuous exposure, and consequently, higher frequency of the mutation.

Discussion: Supplementary Digital Content 3) has been shown previously.M184 V mutation causes high-level resistance to Lamivudine, and therefore the high frequency of the mutation observed in this study is not unusual since the drug is the most common NRTI in use in Ghana.

M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patients.

PMID: 32065630 2020 The Journal of antimicrobial chemotherapy

Abstract: BACKGROUND: M184V/I NRTI resistance mutations can be selected by either lamivudine/emtricitabine or abacavir.

Abstract: CONCLUSIONS: M184V/I as a unique NRTI resistance mutation, regardless of possible selection by regimens containing lamivudine/emtricitabine or abacavir, does not affect the virological response of well-controlled patients who switched to abacavir/lamivudine/dolutegravir for at least 12 months.

Abstract: OBJECTIVES: We assessed the efficacy of abacavir/lamivudine/dolutegravir when used in HIV-infected pretreated patients with an undetectable VL who previously harboured M184V/I as a unique NRTI resistance mutation in a genotypic resistance test and had no resistance to

Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine.

PMID: 32080249 2020 Scientific reports

Abstract: Additionally, we experimentally simulated previously reported ETV/3TC resistance for HBV using HIVY115F/F116Y/Q151M with F160M/M184V (L180M/M204V in HBV RT) substituted.

Abstract: Structural analysis of RTY115F/F116Y/Q151M/F160M/M184V:DNA:3TC-TP also demonstrated that the loosely bound 3TC-TP is misaligned at the active site to prevent a steric clash with the side chain gamma-methyl of Val184.

Introduction: 3TC is also approved as an anti-HIV-1 agent, and M184V in HIV-1 RT, which co

Natural polymorphisms in HIV-1 CRF01_AE strain and profile of acquired drug resistance mutations in a long-term combination treatment cohort in northeastern China.

PMID: 32102660 2020 BMC infectious diseases

Result: Result: Nine known DRMs (K65R, V106 M, Y115F, V179 T/E/D, Y181C, M184 V, and G190S) and two potential new DRMs (V75 L and L228R) were demonstrated to be under positive selection pressure (Ka/Ks > 1, LOD > 2).

Result: The NRTI-associated DRMs detected at TF time point in descending order included K65R (57.1%), M184 V/I (47.6%), S68G (26.2%), A62V (14.3%), K70E/R (9.5%), and Y115F (9.5%).

High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment.

PMID: 32105319 2020 The Journal of antimicrobial chemotherapy

Table: M184V

Synthesis and biological evaluation of a series of 2-(((5-akly/aryl-1H-pyrazol-3-yl)methyl)thio)-5-alkyl-6-(cyclohexylmethyl)-pyrimi din-4(3H)-ones as potential HIV-1 inhibitors.

PMID: 32140396 2020 Acta pharmaceutica Sinica. B

Table: M184V

Multidrug-resistant HIV viral rebound during early syphilis: a case report.

PMID: 32264923 2020 BMC infectious diseases

Abstract: A plasma RNA genotype resistance test revealed wild-type virus in the integrase region and protease region (PR), but extensive resistance in the reverse transcriptase (RT) region (M41L, E44D, D67N, K70R, M184V, L210W and T215Y).

Conclusion: A genotype resistance test (GRT) in June 2002 (Trugene HIV-1 Genotyping Assay, Siemens Healthcare Diagnostics GmbH, Eschborn, Germany) showed extensive resistance in the RT region (M41L, E44D, D67

Near point-of-care, point-mutation test to detect drug resistance in HIV-1: a validation study in a Mexican cohort.

PMID: 32205723 2020 AIDS (London, England)

Introduction: Moreover, an OLA-Simple kit that detects the NRTI mutation M184V and NNRTI mutations K103N, Y181C, and G190A was clinically validated across multiple HIV-1 subtypes, showing 99.6% sensitivity and 98.2% specificity compared to Sanger sequencing.

Method: A database containing HIVDR profiles from 2412 individuals initiating first-line ART in Mexico City genotyped by MiSeq was used to select 60 plasma specimens enriched for mutations K65R, K103N/S, Y181C, M184V, and G190A.

Method: OLA-Simple probes designed to detect K65R,

PMID: 32183889 2020 Virology journal

Abstract: M184V (62.04%), K103N (41.90%) and I54L (3.83%) were the most common observed mutations, respectively, in NRTI-, NNRTI- and PI-associated drug resistance.

Result: The most common primary NRTI mutations detected included M184V (62.04%), K65R (20.24%), K70R (15.01%), T215D/S (9.41%), Y115F (7.22%) and M41L (6.35%).

Table: M184V/I

Browser Board

Co-occurred Entities

Filtrator